u/foam_head_fred

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

symptom patterns can track the cycle rather than the dose

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

symptom patterns can track the cycle rather than the dose

Why the same vial can honestly produce three different numbers.

Purity by area percent is relative to what the detector saw on one gradient at one wavelength. Net peptide content subtracts counterion, water and residual solvent. Mass of peptide per vial is net content times fill weight, and fill weight has its own tolerance.

So a document reading 99% purity, 6% acetate and 4% water is describing a vial that is about 90% peptide by mass, and every one of those numbers is honest. The mistake is treating the headline figure as the answer to "how much peptide did I get".

chromatogram or it did not happen

registry entry, protocol, publication — three different documents

That is the 68-week readout, not the 72-week one. Different trial, different duration.

What was the discontinuation rate?

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

What was the discontinuation rate?

careful_gradient_again is right about the programme names. They are different populations with different endpoints.

Batch number and date of analysis, are both on there?

Telogen shedding follows a period of significant weight change rather than a specific compound, and it resolves.

The one practical change that makes this board’s hardest questions tractable: annotate your log with the cycle.

Hormonal variation affects appetite, fluid and symptom intensity in its own right. Without the annotation, a log shows a dose, a week and a set of symptoms that appear to move at random. With it, patterns that were invisible become obvious in about three months.

Members here who have done it consistently report the same thing: the same dose feels genuinely different at different points, and knowing that in advance converts a confusing fortnight into an expected one. It also makes a much better document to bring to an appointment.

Agreed — logging the cycle alongside everything else is what made my own pattern visible. It was invisible before that.

Absolute or relative risk reduction?

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

batch number, date of analysis, method, individual impurities — that is the minimum set

Adding the bit that always gets missed: the lot on the vial has to match the lot on the page, or none of this applies to your material.

Did you get the chromatogram or only the summary line?

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

This is the check that catches most of it, and it takes under a minute.

rohan_krastev has the group-buy risk right — it is structural, not a judgement about anybody in particular.

That is an accusation about a named individual and it does not belong here in any form.

a total of 0.4% tells you less than four named impurities adding to 0.6%